The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

While Novo Nordisk increased sales and profits last year, the company’s share price took a battering in the second half of 2024. Shareholders faced a 10% loss in the value of their holdings in ...

Novo Nordisk’s CEO toasted the company ... his STIP on the back of huge jumps in the company’s revenues and share price. Jørgensen’s STIP this year, however, came in at 69% of his annual ...

As of 4 February 2025, Novo Nordisk has since 6 February 2024 repurchased a total 24,802,593 B shares at an average share price of DKK 806.37 per B share equal to a transaction value of DKK ...

Novo Nordisk’s CEO toasted the company’s record-breaking ... Last year, Jorgensen nearly maxed out his STIP on the back of huge jumps in the company’s revenues and share price. Jorgensen’s STIP this ...